People Briefs: Mercator, MITA And 23andMe
This article was originally published in The Gray Sheet
Executive Summary
Drug-delivery firm Mercator MedSystems names a new CEO. Also, recent appointments at MITA and 23andMe.
You may also be interested in...
FDA Comes Down Hard On 23andMe, Putting Consumer-Directed Genetic Testing On Notice
The agency tells direct-to-consumer genetic testing company 23andMe in a strongly-worded warning letter that it should immediately stop marketing its Personal Genome Service until it can gain clearance. The firm says it will address the agency’s concerns.
Abbott Ups Vascular, Ophthalmic Focus With Two Acquisitions
Abbott Laboratories announced July 15 it has entered into agreements to purchase stent manufacturer IDev Technologies and ophthalmic device company OptiMedica Corp. The acquisitions are intended to bolster the company’s medical device unit in the vascular and vision care businesses, respectively.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.